Literature DB >> 24995085

Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.

Hui Lin1, Yong-Chun Shen2, Hong-Yu Long2, Hao Wang2, Ze-Yu Luo3, Zi-Xuan Wei3, Shi-Qi Hu3, Fu-Qiang Wen2.   

Abstract

It is reported that osteopontin has shown promising diagnostic value for malignant pleural mesothelioma (MPM), this meta-analysis aimed to establish the overall diagnostic accuracy of the osteopontin measurement for diagnosing MPM. Based on a systematic review of English language studies, the sensitivity, specificity and other measures of accuracy of osteopontin in the diagnosis of MPM were pooled using random-effects model. Summary receiver operating characteristic curves were used to summarize overall test performance. Seven publications met our inclusion criteria, the pooled sensitivity was 0.57 (95%CI: 0.52-0.61), specificity was 0.81, 95%CI: 0.79-0.84). The PLR was 3.78 (95%CI: 2.23-6.41), the NLR was 0.51 (95%CI: 0.38-0.67) and the DOR was 9.04 (95%CI: 5.28-15.48), the area under the summary receiver operating characteristic curve was 0.80. Our data suggest that osteopontin is likely to be a useful diagnostic marker for MPM, considering for the limited studies and patients included, larger studies are needed to confirm these findings.

Entities:  

Keywords:  Osteopontin; malignant pleural mesothelioma; meta-analysis

Year:  2014        PMID: 24995085      PMCID: PMC4073746     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Exploring sources of heterogeneity in systematic reviews of diagnostic tests.

Authors:  Jeroen G Lijmer; Patrick M M Bossuyt; Siem H Heisterkamp
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

3.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

Authors:  N S Fedarko; A Jain; A Karadag; M R Van Eman; L W Fisher
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  Diagnostic performance of lung ultrasound in the diagnosis of pneumonia: a bivariate meta-analysis.

Authors:  Qian-Jing Hu; Yong-Chun Shen; Liu-Qun Jia; Shu-Jin Guo; Hong-Yu Long; Cai-Shuang Pang; Ting Yang; Fu-Qiang Wen
Journal:  Int J Clin Exp Med       Date:  2014-01-15

Review 5.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

6.  Systematic reviews of diagnostic test accuracy.

Authors:  Mariska M G Leeflang; Jonathan J Deeks; Constantine Gatsonis; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2008-12-16       Impact factor: 25.391

7.  Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Yvonne Demelker; Amanda Segal; A W Musk; Steven J Skates; Bruce W S Robinson
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

Review 8.  Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.

Authors:  Ling Luo; Huan-Zhong Shi; Qiu-Li Liang; Jing Jiang; Shou-Ming Qin; Jing-Min Deng
Journal:  Respir Med       Date:  2009-11-30       Impact factor: 3.415

9.  Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.

Authors:  Aliya N Husain; Thomas V Colby; Nelson G Ordóñez; Thomas Krausz; Alain Borczuk; Philip T Cagle; Lucian R Chirieac; Andrew Churg; Francoise Galateau-Salle; Allen R Gibbs; Allen M Gown; Samuel P Hammar; Leslie A Litzky; Victor L Roggli; William D Travis; Mark R Wick
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

Review 10.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more
  7 in total

Review 1.  Malignant Mesothelioma: Time to Translate?

Authors:  Andrea Napolitano; Michele Carbone
Journal:  Trends Cancer       Date:  2016-09

2.  Diagnosis efficiency for pulmonary embolism using magnetic resonance imaging method: a meta-analysis.

Authors:  Kuitao Yue
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.

Authors:  Ran Ren; Pengpeng Yin; Yan Zhang; Jianyun Zhou; Yixing Zhou; Rufu Xu; Hai Lin; Chunji Huang
Journal:  Oncotarget       Date:  2016-12-20

4.  Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.

Authors:  Guntulu Ak; Yuji Tada; Hideaki Shimada; Selma Metintas; Masaaki Ito; Kenzo Hiroshima; Masatoshi Tagawa; Muzaffer Metintas
Journal:  BMC Cancer       Date:  2017-03-23       Impact factor: 4.430

5.  HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.

Authors:  Andrea Napolitano; Daniel J Antoine; Laura Pellegrini; Francine Baumann; Ian Pagano; Sandra Pastorino; Chandra M Goparaju; Kirill Prokrym; Claudia Canino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

6.  Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.

Authors:  Takumi Kishimoto; Yoko Kojima; Nobukazu Fujimoto
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

Review 7.  Biomarkers in the diagnosis of pleural diseases: a 2018 update.

Authors:  José M Porcel
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.